The current research results show that compared to that with azacitidine treatment alone, the overall drug response rate of enasidenib combined with azacitidine is improved, and the combination has good drug tolerance, thereby, improving the prognosis of patients with IDH2 AML (NCT02677922) (Table 2) (DiNardo et al., 2021). This evidence concerns the gene IDH2 and acute myeloid leukemia.